



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## AZD2098

<b>Cat. No.:</b>	HY-U00064		
<b>CAS No.:</b>	566203-88-1		
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>9</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	334.18		
<b>Target:</b>	CCR		
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (299.24 mM; Need ultrasonic)  
 Ethanol : 5 mg/mL (14.96 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9924 mL	14.9620 mL	29.9240 mL
	5 mM	0.5985 mL	2.9924 mL	5.9848 mL
	10 mM	0.2992 mL	1.4962 mL	2.9924 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (7.48 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (7.48 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC<sub>50</sub>s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

CCR4

#### In Vitro

AZD2098 potently inhibits chemokine-induced cellular responses, with pIC<sub>50</sub> of 7.5 and 6.3 against CCL22-induced Ca<sup>2+</sup> influx in hCCR4-expressing CHO cells and CCL17- or CCL22-induced chemotaxis of primary human Th2 cells respectively<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

AZD2098 (73.5-5.0 µg/kg; p.o.; BID; twice a day; 1 hour before and every 12 hours after antigen challenge) exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats, and the changes are first visible at a dose of 0.22 µmol/kg and maximal at 7.5 µmol/kg<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Brown-Norway rats <sup>[1]</sup>
Dosage:	73.5 µg/kg, 250.6 µg/kg, 735.2 µg/kg, 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg
Administration:	Oral administration; twice a day; 1 hour before and every 12 hours after antigen challenge
Result:	Exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats.

## CUSTOMER VALIDATION

- Theranostics. 2021 Feb 6;11(8):3839-3852.
- Cell Death Dis. 2022 Feb 17;13(2):158.
- Int Immunopharmacol. 2024 Feb 19;130:111712.
- Sci Rep. 2020 Nov 25;10(1):20508.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Kindon N, et al. Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. ACS Med Chem Lett. 2017 Sep 1;8(9):981-986.

[2]. Asher Mullard. Cancer charity sees success re-prioritizing industry's shelved compounds. Nat Rev Drug Discov. 2014 May;13(5):319-21.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA